Skip to main content
Explore URMC

menu

Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer

Research Question:
Will patients with HER-2 negative, hormone receptor positive, metastatic breast cancer who are monitored with serum tumor marker directed disease monitoring (STMDDM) have non-inferior overall survival compared to patients monitored with usual care?

Basic Study Information

Purpose:
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using markers to prompt when scans should be ordered may be as good as the usual approach to monitoring disease.

Location: University of Rochester Medical Center
Study Reference #: CBRS18109

Lead Researcher (Principal Investigator)

Lead Researcher: Alissa Huston

Study Contact Information

Study Coordinator: Kathryn Corcoran
Phone: (585) 275-7771
Email: Kathryn_Corcoran@URMC.Rochester.edu

Additional Study Details

Contact This Study

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search